Page 196 - Haematologica May 2022

Letters to the Editor
include the retrospective design, and heterogeneity in clinical practice in regard to diagnosis and management.
In summary, we confirm the infrequent (0.5-2.2%) occurrence of genetic alterations involving the hypoxia pathway, EPOR and BPGM among patients undergoing hereditary erythrocytosis evaluation at the Mayo Clinic which includes testing for all congenital mutations except recently described EPO and iron-responsive element binding protein 1 (IRP1) mutations.17,18 Additionally, phe- notypic correlations and management details are provid- ed which may serve as a useful guide for clinicians.
Naseema Gangat,1 Jennifer L. Oliveira,2 Tavanna R Porter,2 James D. Hoyer,2 Aref Al-Kali,1 Mrinal M Patnaik,1 Animesh Pardanani1 and Ayalew Tefferi1
1Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester and 2Division of Hematopathology, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA.
Correspondence:
NASEEMA GANGAT - gangat.naseema@mayo.edu AYALEW TEFFERI - tefferi.ayalew@mayo.edu doi:10.3324/haematol.2021.280516
Received: December 14, 2021.
Accepted: February 2, 2022.
Pre-published: February 10, 2022.
Disclosures: no conflicts of interest to disclose.
Contributions: NG and AT designed the study, collected data, per- formed analyses and wrote the letter; JLO, TRP and JDH reviewed and interpreted all sequencing data; AA, MMP and AP contributed patients.
Data-sharing statement: data can be obtained by email (gangat.naseema@mayo.edu)
References
1. Gangat N, Szuber N, Pardanani A, Tefferi A. JAK2 unmutated ery- throcytosis: current diagnostic approach and therapeutic views. Leukemia. 2021;35(8):2166-2181.
2. Gangat N, Oliveira JL, Hoyer JD, Patnaik MM, Pardanani A, Tefferi A. High-oxygen-affinity hemoglobinopathy-associated erythrocyto- sis: Clinical outcomes and impact of therapy in 41 cases. Am J Hematol. 2021;96(12):1647-1654.
3. Filser M, Aral B, Airaud F, et al. Low incidence of EPOR mutations in idiopathic erythrocytosis. Haematologica. 2021;106(1):299-301.
4. Oliveira JL, Coon LM, Frederick LA, et al. Genotype-phenotype cor- relation of hereditary erythrocytosis mutations, a single center expe- rience. Am J Hematol. 2018;93(8):1029-1041.
5. Lorenzo FR, Yang C, Ng Tang Fui M, et al. A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paragan- glioma. J Mol Med (Berl). 2013;91(4):507-512.
6. Wilson R, Syed N, Shah P. Erythrocytosis due to PHD2 mutations: a review of clinical presentation, diagnosis, and genetics. Case Rep Hematol. 2016;2016:6373706.
7. Gardie B, Percy MJ, Hoogewijs D, et al. The role of PHD2 mutations in the pathogenesis of erythrocytosis. Hypoxia (Auckl). 2014;2:71- 90.
8. Bento C, Percy MJ, Gardie B, et al. Genetic basis of congenital ery- throcytosis: mutation update and online databases. Hum Mutat. 2014;35(1):15-26.
9. de la Chapelle A, Traskelin AL, Juvonen E. Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis. Proc Natl Acad Sci U S A. 1993;90(10):4495-4499.
10.Hoyer JD, Allen SL, Beutler E, Kubik K, West C, Fairbanks VF. Erythrocytosis due to bisphosphoglycerate mutase deficiency with concurrent glucose-6-phosphate dehydrogenase (G-6-PD) deficiency. Am J Hematol. 2004;75(4):205-208.
11. Lemarchandel V, Joulin V, Valentin C, et al. Compound heterozygos- ity in a complete erythrocyte bisphosphoglycerate mutase deficien- cy. Blood. 1992;80(10):2643-2649.
12. Petousi N, Copley RR, Lappin TR, et al. Erythrocytosis associated with a novel missense mutation in the BPGM gene. Haematologica. 2014;99(10):e201-204.
13. Camps C, Petousi N, Bento C, et al. Gene panel sequencing improves the diagnostic work-up of patients with idiopathic erythrocytosis and identifies new mutations. Haematologica. 2016;101(11):1306- 1318.
14. Gordeuk VR, Sergueeva AI, Miasnikova GY, et al. Congenital disor- der of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnor- malities but not tumors. Blood. 2004;103(10):3924-3932.
15. Gordeuk VR, Miasnikova GY, Sergueeva AI, et al. Thrombotic risk in congenital erythrocytosis due to up-regulated hypoxia sensing is not associated with elevated hematocrit. Haematologica. 2020;105(3):e87-e90.
16. Tarade D, Robinson CM, Lee JE, Ohh M. HIF-2alpha-pVHL complex reveals broad genotype-phenotype correlations in HIF-2alpha-driven disease. Nat Commun. 2018;9(1):3359.
17. Zmajkovic J, Lundberg P, Nienhold R, et al. A gain-of-function muta- tion in EPO in familial erythrocytosis. N Engl J Med. 2018;378(10):924-930.
18. Oskarsson GR, Oddsson A, Magnusson MK, et al. Predicted loss and gain of function mutations in ACO1 are associated with erythro- poiesis. Commun Biol. 2020;3(1):189.
19. Percy MJ, Beer PA, Campbell G, et al. Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis. Blood. 2008;111(11):5400-5402.
20. Percy MJ, Chung YJ, Harrison C, et al. Two new mutations in the HIF2A gene associated with erythrocytosis. Am J Hematol. 2012;87(4):439-442.
1204
haematologica | 2022; 107(5)